GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system

Cell Transplantation

Volumn 22, Issue 11, 2013, Pages 1981-2000

  Rojewski, Markus T ^a,b   Fekete, Natalie ^a,b   Baila, Stefano ^c   Nguyen, Kim ^d   Fürst, Daniel ^b   Antwiler, Delbert ^d   Dausend, Julia ^a   Kreja, Ludwika ^a   Ignatius, Anita ^a   Sensebé, Luc ^e   Schrezenmeier, Hubert ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b Institute of Transfusion Medicine   (Germany)

^c Terumo BCT Europe NV   (Belgium)

^d Terumo BCT   (United States)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Bioreactor; Good manufacturing practice (GMP); Large scale; Mesenchymal stem cells (MSCs)

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CD40 LIGAND; FIBRONECTIN; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LACTIC ACID; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; BIOLOGICAL MARKER; CYTOKINE;

ADIPOGENESIS; ADULT; ARTICLE; AUTOMATED CELL CULTURE HOLLOW FIBER BIOREACTOR QUANTUM CELL EXPANSION SYSTEM; BIOREACTOR; BONE DEVELOPMENT; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL SURFACE; CELL SUSPENSION; CHONDROGENESIS; EX VIVO STUDY; FEMALE; FETAL CALF SERUM; FLOW CYTOMETRY; GAS EXCHANGE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; NORMAL HUMAN; PRIORITY JOURNAL; CELL CULTURE; CELL SEPARATION; CHEMISTRY; CULTURE TECHNIQUE; CYTOLOGY; DEVICES; ENZYME LINKED IMMUNOSORBENT ASSAY; KARYOTYPING; MESENCHYMAL STROMA CELL; METABOLISM; PHENOTYPE; STANDARDS; THROMBOCYTE;

ANIMALIA;

BIOLOGICAL MARKERS; BIOREACTORS; BLOOD PLATELETS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRONECTINS; FLOW CYTOMETRY; HUMANS; KARYOTYPING; MESENCHYMAL STROMAL CELLS; PHENOTYPE;

EID: 84886418978     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X657990     Document Type: Article

References (30)

1. Battula, V. L.; Treml, S.; Bareiss, P. M.; Gieseke, F.; Roelofs, H.; de Zwart, P.; Muller, I.; Schewe, B.; Skutella, T.; Fibbe, W. E.; Kanz, L.; Buhring, H. J. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 94(2):173-184; 2009.
2. Bernardo, M. E.; Cometa, A. M.; Pagliara, D.; Vinti, L.; Rossi, F.; Cristantielli, R.; Palumbo, G.; Locatelli, F. Ex vivo expansion of mesenchymal stromal cells. Best Pract. Res. Clin. Haematol. 24(1):73-81; 2011.
3. Bieback, K.; Schallmoser, K.; Klüter, H.; Strunk, D. Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus. Med. Hemother. 35(4):286-294; 2008.
4. Bouffi, C.; Bony, C.; Courties, G.; Jorgensen, C.; Noel, D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 5(12):e14247; 2010.
5. Buhring, H. J.; Battula, V. L.; Treml, S.; Schewe, B.; Kanz, L.; Vogel, W. Novel markers for the prospective isolation of human MSC. Ann. N.Y. Acad. Sci. 1106:262-271; 2007.
6. Buhring, H. J.; Treml, S.; Cerabona, F.; de Zwart, P.; Kanz, L.; Sobiesiak, M. Phenotypic characterization of distinct human bone marrow-derived MSC subsets. Ann. N.Y. Acad. Sci. 1176:124-134; 2009.
7. Caplan, A. I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol. 213(2):341-347; 2007.
8. Caplan, A. I. The mesengenic process. Clin. Plast. Surg. 21(3):429-435; 1994.
9. Ciuculescu, F.; Giesen, M.; Deak, E.; Lang, V.; Seifried, E.; Henschler, R. Variability in chemokine-induced adhesion of human mesenchymal stromal cells. Cytotherapy 13(10): 1172-1179; 2011.
10. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315-317; 2006.
11. Fazzi, R.; Pacini, S.; Carnicelli, V.; Trombi, L.; Montali, M.; Lazzarini, E.; Petrini, M. Mesodermal progenitor cells (MPCs) Differentiate into mesenchymal stromal cells (MSCs) by activation of Wnt5/calmodulin signalling pathway. PLoS One 6(9):e25600; 2011.
12. Fekete, N.; Gadelorge, M.; Furst, D.; Maurer, C.; Dausend, J.; Fleury-Cappellesso, S.; Mailander, V.; Lotfi, R.; Ignatius, A.; Sensebe, L.; Bourin, P.; Schrezenmeier, H.; Rojewski, M. T. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: Production process, content and identification of active components. Cytotherapy 14(5):540-554; 2012.
13. Kim, D. S.; Kim, J. H.; Lee, J. K.; Choi, S. J.; Kim, J. S.; Jeun, S. S.; Oh, W.; Yang, Y. S.; Chang, J. W. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev. 18(3):511-519; 2009.
14. Kuci, S.; Kuci, Z.; Kreyenberg, H.; Deak, E.; Putsch, K.; Huenecke, S.; Amara, C.; Koller, S.; Rettinger, E.; Grez, M.; Koehl, U.; Latifi-Pupovci, H.; Henschler, R.; Tonn, T.; von, L. D.; Klingebiel, T.; Bader, P. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 95(4):651-659; 2010.
15. Liu, C. H.; Hwang, S. M. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32(6):270-279; 2005.
16. Mafi, R.; Hindocha, S.; Mafi, P.; Griffin, M.; Khan, W. S. Sources of adult mesenchymal stem cells applicable for musculoskeletal applications-a systematic review of the literature. Open Orthop. J. 5(Suppl 2):242-248; 2011.
17. Nguyen, K.; Brecheiesen, M.; Peters, R.; Startz, T.; Vang, B.; Baila, S. Quantum® cell expansion system-automated expansion of human mesenchymal stem cells from precultured cells using the Quantum cell expansion system. TERUMO BCT:http://www.terumobct.com/location/northamerica/Documents/THX_Quantum_MSC_WP_8.5x11_V12_14.pdf; 2012.
18. Peters, A. L.; Stunz, L. L.; Bishop, G. A. CD40 and autoimmunity: The dark side of a great activator. Semin. Immunol. 21(5):293-300; 2009.
19. Phinney, D. G.; Kopen, G.; Righter, W.; Webster, S.; Tremain, N.; Prockop, D. J. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J. Cell. Biochem. 75(3):424-436; 1999.
20. Pricola, K. L.; Kuhn, N. Z.; Haleem-Smith, H.; Song, Y.; Tuan, R. S. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J. Cell. Biochem. 108(3):577-588; 2009.
21. Rojewski, M. T.; Weber, B. M.; Schrezenmeier, H. Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus. Med. Hemother. 35(3):168-184; 2008.
22. Ruster, B.; Gottig, S.; Ludwig, R. J.; Bistrian, R.; Muller, S.; Seifried, E.; Gille, J.; Henschler, R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108(12):3938-3944; 2006.
23. Schumacher, C.; Clark-Lewis, I.; Baggiolini, M.; Moser, B. High- and low-affinity binding of GRO a and neutrophil- activating peptide 2 to interleukin-8 receptors on human neutrophils. Proc. Natl. Acad. Sci. USA 89(21):10542-10546; 1992.
24. Siddappa, R.; Licht, R.; van Blitterswijk, C.; de Boer, J. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J. Orthop. Res. 25(8):1029-1041; 2007.
25. Singer, N. G.; Caplan, A. I. Mesenchymal stem cells: Mechanisms of inflammation. Ann. Rev. Pathol. Mech. Dis. 6(1):457-478; 2011.
26. Spaeth, E. L.; Dembinski, J. L.; Sasser, A. K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4):e4992; 2009.
27. Subbanna, P. K. T. Mesenchymal stem cells for treating GVHD: In vivo fate and optimal dose. Med. Hypotheses 69(2):469-470; 2007.
28. Tautzenberger, A.; Lorenz, S.; Kreja, L.; Zeller, A.; Musyanovych, A.; Schrezenmeier, H.; Landfester, K.; Mailander, V.; Ignatius, A. Effect of functionalised fluorescence- labelled nanoparticles on mesenchymal stem cell differentiation. Biomaterials 31(8):2064-2071; 2010.
29. Wuyts, A.; Govaerts, C.; Struyf, S.; Lenaerts, J. P.; Put, W.; Conings, R.; Proost, P.; Van Damme, J. Isolation of the CXC chemokines ENA-78, GRO a and GRO g from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur. J. Biochem. 260(2):421-429; 1999.
30. Yagi, H.; Soto-Gutierrez, A.; Parekkadan, B.; Kitagawa, Y.; Tompkins, R. G.; Kobayashi, N.; Yarmush, M. L. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 19(6):667-679; 2010.